Clinicopathological Characteristics of Human Epidermal Growth Factor Receptor 2-positive Barrett's Adenocarcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2012 Nov 28

PMID 23180947

Citations 4

Authors

Takehiro Tanaka

Atsushi Fujimura

Koichi Ichimura

Hiroyuki Yanai

Yasuharu Sato

Katsuyohi Takata

Hiroyuki Okada

Seiji Kawano

Shunsuke Tanabe

Tadashi Yoshino

Affiliations

Soon will be listed here.

Abstract

Aim: To compare the clinicopathological characteristics of human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative Barrett's adenocarcinoma in Japan.

Methods: We performed immunohistochemical analysis of HER2 in 30 samples taken from patients with Barrett's adenocarcinoma and dual color in situ hybridization in cases showing 2+ reactions. We compared the clinicopathological characteristics of HER2-positive and HER2-negative patients.

Results: HER2 positivity was identified in 8 (27%) carcinoma samples. We found that HER2 expression was associated with p53 overexpression (100% vs 52.6% in pT1 tumor; 100% vs 54.5% in all stage tumor, P < 0.05) and protruding lesions at the early disease stage. There was no association between the mucin phenotype of the carcinomas and prognosis. HER2 expression and low clinical stage were unexpectedly different between Barrett's adenocarcinoma patients and gastric cancer patients, but the macroscopic features may be associated with earlier diagnosis in these patients.

Conclusion: Our results suggest that HER2-positive Barrett's adenocarcinomas are associated with p53 overexpression and lesion protrusion at the early disease stage.

Citing Articles

Sticking to the Problem: Engineering Adhesion in Molecular Endoscopic Imaging.

Noori M, Bodle S, Showalter C, Streator E, Drozek D, Burdick M Cell Mol Bioeng. 2020; 13(2):113-124.

PMID: 32175025 PMC: 7048886. DOI: 10.1007/s12195-020-00609-0.

HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies.

Ieni A, Cardia R, Pizzimenti C, Zeppa P, Tuccari G J Pers Med. 2020; 10(1).

PMID: 32098203 PMC: 7151629. DOI: 10.3390/jpm10010010.

Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma.

Almhanna K, Rosa M, Henderson-Jackson E, Jiang K, Shamekh R, Sayegh Z Appl Immunohistochem Mol Morphol. 2015; 24(9):633-638.

PMID: 26186253 PMC: 7771552. DOI: 10.1097/PAI.0000000000000243.

Molecular markers and imaging tools to identify malignant potential in Barrett's esophagus.

Bennett M, Mashimo H World J Gastrointest Pathophysiol. 2014; 5(4):438-49.

PMID: 25400987 PMC: 4231508. DOI: 10.4291/wjgp.v5.i4.438.

References

Park D, Srivastava A, Kim G, Mino-Kenudson M, Deshpande V, Zukerberg L . Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia. Am J Surg Pathol. 2008; 32(4):524-33. DOI: 10.1097/PAS.0b013e31815b890e. View

Al-Kasspooles M, Moore J, Orringer M, Beer D . Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer. 1993; 54(2):213-9. DOI: 10.1002/ijc.2910540209. View

Polkowski W, van Sandick J, Offerhaus G, Ten Kate F, Mulder J, Obertop H . Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1999; 6(3):290-7. DOI: 10.1007/s10434-999-0290-2. View

Moore J, Lesser E, Erdody D, Natale R, Orringer M, Beer D . Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer. 1994; 56(4):487-93. DOI: 10.1002/ijc.2910560406. View

Yoon H, Shi Q, Sukov W, Wiktor A, Khan M, Sattler C . Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012; 18(2):546-54. PMC: 3261584. DOI: 10.1158/1078-0432.CCR-11-2272. View

Walch A, Specht K, Bink K, Zitzelsberger H, Braselmann H, Bauer M . Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Lab Invest. 2001; 81(6):791-801. DOI: 10.1038/labinvest.3780289. View

Al-Moundhri M, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M . The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol. 2005; 91(4):243-52. DOI: 10.1002/jso.20324. View

Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H . HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2012; 16(1):84-93. DOI: 10.1007/s10120-012-0150-9. View

Brien T, Odze R, Sheehan C, McKenna B, Ross J . HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol. 2000; 31(1):35-9. DOI: 10.1016/s0046-8177(00)80195-1. View

10.

Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura R, Penault-Llorca F . HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012; 25(5):637-50. DOI: 10.1038/modpathol.2011.198. View

11.

Jass J . Discrepancies between East and West. Cancer. 2000; 88(5):969-70. DOI: 10.1002/(sici)1097-0142(20000301)88:5<969::aid-cncr2>3.0.co;2-d. View

12.

Rossi E, Villanacci V, Bassotti G, Casa D, Missale G, Minelli L . Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol. 2006; 15(3):125-30. DOI: 10.1097/01.pdm.0000213455.22527.f7. View

13.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

14.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L . Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14(3):737-44. DOI: 10.1200/JCO.1996.14.3.737. View

15.

Thompson S, Sullivan T, Davies R, Ruszkiewicz A . Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol. 2011; 18(7):2010-7. DOI: 10.1245/s10434-011-1554-1. View

16.

Hongo M . Review article: Barrett's oesophagus and carcinoma in Japan. Aliment Pharmacol Ther. 2004; 20 Suppl 8:50-4. DOI: 10.1111/j.1365-2036.2004.02230.x. View

17.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

18.

Tatematsu M, Tsukamoto T, Inada K . Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci. 2003; 94(2):135-41. PMC: 11160206. DOI: 10.1111/j.1349-7006.2003.tb01409.x. View

19.

Hardwick R, Shepherd N, Moorghen M, Newcomb P, Alderson D . c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. J Clin Pathol. 1995; 48(2):129-32. PMC: 502378. DOI: 10.1136/jcp.48.2.129. View

20.

Rucker-Schmidt R, Sanchez C, Blount P, Ayub K, Li X, Rabinovitch P . Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol. 2009; 33(6):886-93. PMC: 2702161. DOI: 10.1097/PAS.0b013e318198a1d4. View